Simpson-Golabi-Behmel syndrome
Rare disease
Yes
- Definition
- Simpson-Golabi-Behmel syndrome is a rare X-linked multiple congenital anomalies syndrome, characterized by pre- and postnatal overgrowth, distinctive craniofacial features, variable congenital malformations, organomegaly and an increased tumor risk.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Simpson-Golabi-Behmel syndrome
- Simpson-Golabi-Behmel syndrome
- DGSX
- Golabi-Rosen syndrome
- SDYS
- SGB syndrome
- SGBS
- Sara Angers syndrome
- Simpson-Golabi-Behmel syndrome
- X-linked dysplasia gigantism syndrome
- Severity
- Severe
- Developmental
- Syndromic
- MONDO ID
- MONDO:0010731
- Parent condition
- MONDO:0002254
Related records
Broader conditions (7)
- Disease
- Disease by body system or component
- Disease by developmental or physiological process
- Disorder of development or morphogenesis
- Human disease
- Overgrowth syndrome
- Syndromic disease
Narrower conditions (2)
- Simpson-Golabi-Behmel syndrome type 1
- Simpson-Golabi-Behmel syndrome type 2
Trials (15)
- A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
- A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment
- A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC
- A Study to Evaluate the Tolerability, Safety, and PK of AST-201 in Patients With GPC3-positive Advanced Solid Tumors
- Assessment of Glypican 3 as Apredictive Marker in Colorectal Cancer Patients
- CAR-T Cell Immunotherapy for HCC Targeting GPC3
- Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC
- First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours
- Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
- GPC3 CAR T Cells With IL-15 and IL-21 for Recurrent ATRT and CNS Rhabdoid Tumors (RADIANT)
- GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression
- GPC3-targeted CAR-T Cell for Treating GPC3 Positive Advanced HCC
- GPC3-Targeted PET/CT in Hepatocellular Carcinoma
- Risk Factors of Atrial Fibrillation After Cardiac Surgery
- Target-specific immunoPET Imaging of Digestive System Carcinoma